This session covers new AASLD guidelines for screening, disease associations, diagnosis, and treatments.CME/CE Expiration Date: 10/27/26
|
This presentation will provide clinicians a brief scientific overview of 10 of the most controversial topics covered, discussed, and published in OMA’s Clinical Practice Statements, including:
|
Dr. Myriam Modestin-Sorrentino will speak on the need to raise awareness and understanding how the the obesity affects maternal and fetal health.
|
Treatment of people with unhealthy weight has typically focused on those with obesity or in those with BMI ≥ 27 with existing comorbidities; however, evidence indicates that the negative effects of
|
Demand for pharmacotherapy has increased considerably with the introduction of newer anti-obesity medications (AOM’s).
|
This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMO
|
In adolescents and adults, the co-occurrence of eating disorders and overweight or obesity is continuing to increase.
|
Obesity is a complex phenotype reflecting the interactions of numerous genes that have been “selected” for in service of reproductive integrity with modern environments.
|
Intermittent Fasting (IF) as a means of dietary modification has gained popularity among individuals with obesity as a means of achieving weight loss.
|
Individual patient response to nutritional therapies varies widely.
|